RS56544B1 - Supstituisani 2-alkil-1-okso-n-fenil-3-heteroaril-1,2,3,4-tetrahidroizohinolin-4-karboksamidi za antimalarijske terapije - Google Patents

Supstituisani 2-alkil-1-okso-n-fenil-3-heteroaril-1,2,3,4-tetrahidroizohinolin-4-karboksamidi za antimalarijske terapije

Info

Publication number
RS56544B1
RS56544B1 RS20171090A RSP20171090A RS56544B1 RS 56544 B1 RS56544 B1 RS 56544B1 RS 20171090 A RS20171090 A RS 20171090A RS P20171090 A RSP20171090 A RS P20171090A RS 56544 B1 RS56544 B1 RS 56544B1
Authority
RS
Serbia
Prior art keywords
oxo
tetrahydroisoquinoline
carboxamide
pyrazol
isobutyl
Prior art date
Application number
RS20171090A
Other languages
English (en)
Serbian (sr)
Inventor
Rodney Kiplin Guy
Fangyi Zhu
Wendyam Armand Guiguemde
David Floyd
Spencer Knapp
Philip Stein
Steve Castro
Original Assignee
St Jude Childrens Res Hospital
Medicines For Malaria Venture Mmv
Rutgers The State University Of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Jude Childrens Res Hospital, Medicines For Malaria Venture Mmv, Rutgers The State University Of New Jersey filed Critical St Jude Childrens Res Hospital
Publication of RS56544B1 publication Critical patent/RS56544B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RS20171090A 2011-08-25 2012-08-24 Supstituisani 2-alkil-1-okso-n-fenil-3-heteroaril-1,2,3,4-tetrahidroizohinolin-4-karboksamidi za antimalarijske terapije RS56544B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161527594P 2011-08-25 2011-08-25
PCT/IB2012/054305 WO2013027196A1 (en) 2011-08-25 2012-08-24 Substituted 2-alkyl-1-oxo-n-phenyl-3-heteroaryl-1,2,3,4- tetrahydroisoquinoline-4-carboxamides for antimalarial therapies
EP12772470.6A EP2748147B1 (en) 2011-08-25 2012-08-24 Substituted 2-alkyl-1-oxo-n-phenyl-3-heteroaryl-1,2,3,4-tetrahydroisoquinoline-4-carboxamides for antimalarial therapies

Publications (1)

Publication Number Publication Date
RS56544B1 true RS56544B1 (sr) 2018-02-28

Family

ID=47018313

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20171090A RS56544B1 (sr) 2011-08-25 2012-08-24 Supstituisani 2-alkil-1-okso-n-fenil-3-heteroaril-1,2,3,4-tetrahidroizohinolin-4-karboksamidi za antimalarijske terapije

Country Status (19)

Country Link
US (1) US9416124B2 (enExample)
EP (1) EP2748147B1 (enExample)
JP (1) JP6035334B2 (enExample)
CN (1) CN103930404B (enExample)
BR (1) BR112014004437B1 (enExample)
CA (1) CA2846507C (enExample)
CY (1) CY1119748T1 (enExample)
DK (1) DK2748147T3 (enExample)
ES (1) ES2644082T3 (enExample)
HR (1) HRP20171567T1 (enExample)
HU (1) HUE034721T2 (enExample)
LT (1) LT2748147T (enExample)
ME (1) ME02908B (enExample)
PL (1) PL2748147T3 (enExample)
PT (1) PT2748147T (enExample)
RS (1) RS56544B1 (enExample)
SI (1) SI2748147T1 (enExample)
SM (1) SMT201700528T1 (enExample)
WO (1) WO2013027196A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111886225A (zh) * 2017-08-21 2020-11-03 纳维根公司 Arf6抑制剂及相关方法
EP3892332A1 (en) 2020-04-09 2021-10-13 University Of Kentucky Research Foundation New anti-malarial agents
CA3214899A1 (en) 2021-04-15 2022-10-20 Lutz Weber Isoquinoline derivatives for use as antiviral and antitumour agents
EP4074314A1 (en) 2021-04-15 2022-10-19 Valdospan GmbH Isoquinoline derivatives for use as antiviral and antitumour agents
AU2023363824A1 (en) 2022-10-17 2025-04-17 Rdp Pharma Ag Isoquinoline derivatives as protein degraders, e7 degraders, antivirals, tumor therapeutics and immune suppressives

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5409938A (en) * 1994-02-14 1995-04-25 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Antimalarial korupensamines and pharmaceutical compositions and medical uses thereof
US5639761A (en) * 1994-02-14 1997-06-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antimalarial naphthylisoquinoline alkaloids and pharmaceutical compositions and medical uses thereof
US6921762B2 (en) * 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
WO2004004727A1 (en) 2002-07-03 2004-01-15 Axys Pharmaceuticals, Inc. 3,4-dihydroisoquinolin-1-one derivatives as inducers of apoptosis
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
DE10312963A1 (de) 2003-03-24 2004-10-07 Aventis Pharma Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
UY29440A1 (es) * 2005-03-25 2006-10-02 Glaxo Group Ltd Nuevos compuestos
RU2302417C1 (ru) * 2006-03-14 2007-07-10 Иващенко Андрей Александрович 1-оксо-3-(1н-индол-3-ил)-1,2,3,4-тетрагидроизохинолины, способы их получения, комбинаторная библиотека и фокусированная библиотека
BRPI0912871A2 (pt) * 2008-05-19 2015-10-20 Actelion Pharmaceuticals Ltd novas tetraidroisoquinolinas como agentes antimaláricos.
GB0820856D0 (en) 2008-11-14 2008-12-24 Univ Leuven Kath Novel inhibitors of flavivirus replication

Also Published As

Publication number Publication date
BR112014004437A8 (pt) 2018-01-23
CN103930404A (zh) 2014-07-16
BR112014004437B1 (pt) 2021-12-14
ME02908B (me) 2018-10-20
US20140235593A1 (en) 2014-08-21
CN103930404B (zh) 2016-08-24
BR112014004437A2 (pt) 2017-03-28
HUE034721T2 (hu) 2018-02-28
SMT201700528T1 (it) 2018-01-11
DK2748147T3 (da) 2017-11-13
EP2748147B1 (en) 2017-08-02
EP2748147A1 (en) 2014-07-02
ES2644082T3 (es) 2017-11-27
PT2748147T (pt) 2017-11-14
US9416124B2 (en) 2016-08-16
WO2013027196A9 (en) 2013-04-18
JP6035334B2 (ja) 2016-11-30
WO2013027196A1 (en) 2013-02-28
LT2748147T (lt) 2017-10-25
JP2014524464A (ja) 2014-09-22
PL2748147T3 (pl) 2018-01-31
HK1199443A1 (en) 2015-07-03
CA2846507A1 (en) 2013-02-28
CA2846507C (en) 2020-03-10
CY1119748T1 (el) 2018-06-27
HRP20171567T1 (hr) 2017-11-17
SI2748147T1 (sl) 2017-11-30

Similar Documents

Publication Publication Date Title
US20250388562A1 (en) Small molecule degraders of helios and methods of use
US11396495B2 (en) Amine compound for inhibiting SSAO/VAP-1 and use thereof
US10925874B2 (en) Substituted pyrazolopyrimidines as glucocerebrosidase activators
AU2016204745B2 (en) Pyruvate kinase m2 modulators, therapeutic compositions and related methods of use.
US8883812B2 (en) Piperidinyl pyrimidine amides as Kv7 potassium channel openers
CN108697684A (zh) 趋化因子受体的调节剂
US20220040317A1 (en) Degradation of fak or fak and alk by conjugation of fak and alk inhibitors with e3 ligase ligands and methods of use
US20100298285A1 (en) Biclycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof
JP2012532136A (ja) 治療組成物および関連する使用方法
RS56544B1 (sr) Supstituisani 2-alkil-1-okso-n-fenil-3-heteroaril-1,2,3,4-tetrahidroizohinolin-4-karboksamidi za antimalarijske terapije
JP2021536496A (ja) フェノキシ−ピリジル−ピリミジン化合物及び使用方法
KR20130122531A (ko) Mglur5 양성 알로스테릭 조절물로서 치환된 6­메틸니코틴아미드
CN101687801A (zh) 用作癌症治疗的萘甲酸酰胺的醚
US20170210741A1 (en) Benzimidazole Compounds, Use As Inhibitors of WNT Signaling Pathway in Cancers, and Methods for Preparation Thereof
EP3562821B9 (en) Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase
JP7098826B2 (ja) ピリミジニル-ヘテロアリールオキシ-ナフチル化合物および使用方法
HK1199443B (en) Substituted 2-alkyl-1-oxo-n-phenyl-3-heteroaryl-1,2,3,4-tetrahyd roisoquinoline-4-carboxamides for antimalarial therapies
JPWO2018079629A1 (ja) 抗マラリア活性を有する新規ピリミジン誘導体